Pharmaceutical The US Food and Drug Administration’s actions were behind some of the leading pharma and biotech news last week. This included marketing approval for Johnson & Johnson’s plaque psoriasis drug candidate Tremfya and Gilead Sciences latest hepatitis C drug Vosevi, as well as a setback for Amgen’s osteoporosis treatment Evenity. Added to this, was the welcome news that Novartis and Amgen’s migraine drug erenumab New Drug Application has been accepted by the agency. 23 July 2017